α7 nicotinic acetylcholine receptors (α7nAChRs), expressed in neurons and astrocytes at lower levels, have been implicated in neuroinflammatory and neurodegenerative processes associated with Alzheimer’s disease (AD). Evidence suggests that α7nAChRs interact with soluble amyloid-β (Aβ), contributing to reactive astrogliosis and formation of Aβ plaques in AD.
A recent study in Respiratory Research further investigated the expression and role of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in a horse model of asthma.
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and medical research charity Lifearc have announced a collaboration to develop an affordable and accessible monoclonal antibody (mAb) therapeutic for Crimean-Congo hemorrhagic fever virus (CCHFV).
Aclaris Therapeutics Inc. has gained IND clearance from the FDA for ATI-052, a bispecific anti-thymic stromal lymphopoietin (TSLP)/interleukin-4 receptor (IL-4R) monoclonal antibody being developed to treat certain immuno-inflammatory diseases. A phase Ia/Ib trial, including a proof-of-concept portion in an undisclosed indication, will begin in the current quarter.
Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The phase I/II study will evaluate ETX-636 administered alone and in combination with fulvestrant in participants with advanced solid tumors, including breast cancer, harboring a PI3Kα mutation.
RSS
